The director of lab oversight for the Oklahoma Medical Marijuana Authority, Lee Rhoades, said the agency has done an analysis to determine the priority for the industry: “Is it in contaminants, or is it in THC potency?
“And of course we’ve been hearing quite a while that THC variability is the big issue; the data bore that out,” Rhoades said in a Tulsa World interview last month.
One of the issues with variability in potency test result could stem from THC analogues, according to Rhoades and the team at Genesis.
These not-often naturally occurring compounds, such as THC-O-acetate, were developed in spray form during post-World War II U.S. military research, Brixey said. His team theorizes that some chemist-opportunists have been spraying medical marijuana plant material with the cannabinoid because it can result in a higher THC potency result.
Growers sometimes choose to pay a different lab that generates “better” results to get more in payment for their harvests.
But the legislation that’s needed to effect change has to go beyond THC potency and analogues, Rhoades said, to “anything that might be detected that might be detrimental to a patient’s health.”
Be the first to comment